Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04577300 · ClinicalTrials.gov registry record · Phase 2
Dual Intravitreal Implantation of NT-501 Encapsulated Cell Therapy for Glaucoma
A Phase 2 study of Glaucoma, sponsored by Stanford University.
- Active
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT04577300: Active Phase 2 study of Glaucoma, sponsored by Stanford University.
NCT04577300 is a Phase 2 study of Glaucoma that is active but no longer recruiting, run by Stanford University. The registered enrollment target is 30 participants, below the 910-participant average among 92 other Glaucoma trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04577300, a Phase 2 study of Glaucoma, is active but no longer recruiting, sponsored by Stanford University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine the safety and efficacy over 24 months of dual NT-501 CNTF encapsulated cell therapy (ECT) on visual impairment related to glaucoma.
Primary Outcome
Change from baseline in visual field through 12 months as assessed by Mean Deviation (MD).
Conditions Studied
Interventions
- OTHER Sham comparator
- DRUG NT-501
Study Locations (1)
California
- Byers Eye Institute at Stanford University - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2021-05-15 |
| Est. Completion | 2026-08-15 |
| Phase | Phase 2 |
What the registry record for NCT04577300 still lists
NCT04577300 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 910-participant average among 92 other Glaucoma trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Glaucoma appearing as the primary indexed condition, and to 2 interventions - of which Sham comparator is the first listed.
NCT04577300 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04577300 about?
NCT04577300 is a clinical study titled "Dual Intravitreal Implantation of NT-501 Encapsulated Cell Therapy for Glaucoma". To determine the safety and efficacy over 24 months of dual NT-501 CNTF encapsulated cell therapy (ECT) on visual impairment related to glaucoma.
What is the current status of trial NCT04577300?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2021-05-15. Estimated completion is 2026-08-15.
What conditions does trial NCT04577300 study?
This clinical trial studies the following conditions: Glaucoma.
What interventions are being tested in trial NCT04577300?
The interventions under investigation include: Sham comparator (OTHER), NT-501 (DRUG).
Who is sponsoring clinical trial NCT04577300?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04577300 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glaucoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04577300's enrollment target sits among peer trials
30 79th of 92 higher than 11 of 92 other Glaucoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glaucoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension
RECRUITING · Phase 2
-
Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
RECRUITING · Phase 2
-
Study of NT-501 Encapsulated Cell Therapy for Glaucoma Neuroprotection and Vision Restoration
ACTIVE NOT RECRUITING · Phase 2
-
Circadian Rhythms of Aqueous Humor Dynamics in Humans
COMPLETED · Phase 2
-
Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma
COMPLETED · Phase 2
-
A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular Hypertension
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI